Advances in the Treatment of HER2-Positive Breast Cancer

William J. Gradishar, MD, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses advances in the last year in the treatment of patients with HER2-positive breast cancer.

<<<

Back to the Breast Cancer Special Report

Articles in this issue

almost 12 years ago

Article

Breast Ultrasound Added to Mammography Increases Cancer Detection

almost 12 years ago

Article

Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debuted

almost 12 years ago

Article

Anti-Androgen Not for Male Cancers Alone

almost 12 years ago

Article

Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBC

almost 12 years ago

Article

Obesity as a Risk Factor for Inflammatory Breast Cancer

almost 12 years ago

Article

Immune Checkpoint Inhibition in Breast Cancer

Stay up to date on practice-changing data in community practice.

Related to this article

October 15th, 2026

Neoadjuvant T-DXd Clouds Residual Disease Decisions in HER2+ Breast Cancer

During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.

October 9th, 2026

Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP

ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.